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Abstract: 
Study Design. Cost-effectiveness analysis 
Objective. To evaluate the cost-effectiveness of intradiscal electrothermal therapy (IDET) 
relative to circumferential lumbar fusion with femoral ring allograft (FRA) in UK. 
Summary of Background Data. Circumferential lumbar fusion is an established treatment for 
discogenic low back pain. However, IDET could be a cost-effective treatment alternative as it 
can be carried out as a day case. 
Methods. Patient-level data were available for patients with discogenic low back pain treated 
with FRA (n=37) in a randomized trial of FRA vs titanium cage, and for patients recruited to a 
separate study evaluating the use of IDET (n=85). Both studies were carried out at a single 
institution in the UK. Patients were followed-up for 24 months, with data collected on low 
back disability (Oswestry Disability Index), back and leg pain (visual analogue scale), quality 
of life (SF-36), radiographic evaluations, and NHS resource use. Cost-effectiveness was 
measured by the incremental cost per quality-adjusted life year (QALY) gained. 
 Results. Both treatments produced statistically significant improvements in outcome at 24-
month follow-up. NHS costs were significantly lower with IDET due to a shorter mean 
procedure time (377.4 minutes vs 49.9 minutes) and length of stay (7 days vs 1.2 days). At a 
threshold of £20,000 per QALY, the probability that IDET is cost-effective is high. 
Conclusions. Both treatments led to significant improvements in patient outcomes which 
were sustained for at least 24 months. Costs were lower with IDET, and for appropriate 
patients IDET is an effective and cost-effective treatment alternative. 
 
Key Words: intradiscal electrothermal therapy (IDET), spinal fusion, cost-effectiveness, discogenic 
low back pain 
 
Key Points 
1. Circumferential lumbar fusion is an established treatment for discogenic low back pain. 
However, fusion is an invasive surgical procedure. IDET is a minimally invasive procedure 
which can be carried out on an outpatient basis. In principal, IDET could offer a cost-effective 
treatment alternative. 
2. In two studies involving populations of patients with discogenic low back pain, both 
circumferential fusion and IDET produced statistically significant improvements in back and 
leg pain, low back pain disability and quality of life. 
3. Treatment costs were significantly lower with IDET because of its shorter procedure time 
and length of inpatient stay. In appropriate patients, IDET is a cost-effective treatment 
alternative. 
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Precis 
Cost-effectiveness of intradiscal electrothermal therapy (IDET) is compared with circumferential 
lumbar fusion in patients with discogenic low back pain. Both treatments produced statistically 
significant improvements in pain, low back pain disability and quality of life. Treatment costs 
were significantly lower with IDET, and this is a cost-effective treatment alternative. 
 
Introduction 
Experimental and clinical evidence has established that degeneration of the lumbar intervertebral 
discs is a primary source of refractory low back pain for millions of patients worldwide.1-4 Discogenic 
pain may be a result of repetitive injury and subsequent repair mechanisms leading to vascularized 
and innervated granulation tissue along torn annular fissures.5-6 A recently published case-control 
study found that the presence of severe back pathology was associated with two-fold higher odds of 
having chronic low back pain.7 
 
Spinal fusion is an established surgical treatment for discogenic low back pain. McKenna, et al 
(2005)8 report results of a randomized controlled trial of two forms of circumferential lumbar fusion 
using either a femoral ring allograft (FRA) or a titanium cage (TC). On the basis of the results of this 
trial, Freeman et al (2007)9 demonstrated the superior cost-effectiveness of FRA from the 
perspective of the UK National Health Service (NHS). However, because rigid fusion of the spine is 
invasive and may propagate adjacent-level disc degeneration,10-11 there has been an impetus to 
adopt minimally-invasive interventions that preserve the native disc structure and maintain 
physiologic motion. Intradiscal electrothermal therapy (IDET) (Smith & Nephew, London, UK) is a 
minimally invasive outpatient procedure in which controlled levels of heat are applied directly to the 
affected disc by means of a navigable intradiscal catheter. Regarding mechanism of pain relief, we 
believe that thermal ablation of neoinnervation/ neovascularization of the posterior annulus (as 
described by Freemont et al) is a plausible explanation12. Due to the fact that the procedure can be 
carried out on an outpatient basis, IDET should be less costly than fusion.   
 
A cost-utility analysis has been carried out to evaluate the cost-effectiveness of IDET relative to 
circumferential lumbar fusion with FRA from the perspective of the NHS. The analysis compares 
costs to the NHS in the two years following primary intervention and the gain in patient utility 
between the immediate pre-operative period and two years post-intervention.  Cost-effectiveness is 
measured by the incremental cost per quality-adjusted life year (QALY) gained. 
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Materials and Methods 
Data sources 
Patient-level data were available for all of the patients treated with FRA in the single-center trial of 
FRA vs TC reported by McKenna, et al (2005)8 carried out at Queen’s Medical Centre (QMC), 
Nottingham. One of the present authors (MPG) was investigator in that study. Seventy-eight 
randomized patients received treatment with FRA (n=37) or TC (n=41). Inclusion criteria were 
degenerative disc disease between L3 and S1 with a maximum of two consecutive motion segments 
to be instrumented, pain or functional deficit pre-operatively for a minimum of 6 months and failure 
to respond to conservative treatment for at least 3 months.  Patients were aged 18-70 years. 
Diagnostic criteria for inclusion required radiographic evidence of sclerosis, osteophyte formation, 
degenerative changes of facet joints or greater than 50% collapse of the disc interspace; 3.5 mm or 
more movement on flexion/extension radiographs; MRI evidence of dehydration of the lumbar disc 
with or without reactive sclerosis of the adjacent vertebral body; and discographic evidence of 
abnormal disc morphology with concordant pain on provocation. Exclusion criteria included skeletal 
immaturity or patients over 70 years, more than two levels involved, previous spinal fusion, 
spondylolisthesis of Meyerding grade II or greater, active or systemic infection, osteoporosis or the 
presence of active malignancy.  
 
Patients were followed-up for a minimum of 24 months, with data collected on the Oswestry 
Disability Index (ODI)13 measuring the extent of low back pain disability on a scale from 0%-20% 
(minimal disability) to 100% (bed-bound); Visual Analogue Scale (VAS) measuring back and leg pain 
severity, scaled from 0 cm (no pain) to 10 cm (worst imaginable pain); the Short-Form 36 (SF-36) 
measuring quality of life; radiographic evaluations; NHS resource use and employment status. The 
study ran from February 1998 to October 2002 (inclusive of enrolment and final follow-up). 
 
A separate study to evaluate the use of IDET in patients with chronic discogenic low back pain was 
carried out at QMC between January 2001 and December 2004. The protocol used was part of a 
global post-marketing surveillance study initiated by DePuy Spine (Johnson & Johnson, Leeds, UK). 
All presenting patients meeting the inclusion and exclusion criteria were treated with IDET. Inclusion 
criteria were symptomatic disc degeneration as demonstrated by concordant pain production with 
provocative discography at low volume injection (< 1.5 millilitre dye volume) at levels L3/4, L4/5 or 
L5/S1 without pain reproduction or with discordant pain at adjacent discs; chronic function-limiting 
low back pain of at least 6 months duration; failure to adequately improve following 8-12 weeks of 
conservative treatment; lumbar disc degeneration confirmed using MRI with no more than a 50% 
loss of disc height at the levels to be treated. Exclusion criteria were age <18 years, previous spinal 
surgery at the levels to be treated, spinal fracture, tumour, retrolisthesis, anterior listhesis, scoliosis, 
infection, spinal stenosis, spondylolithesis, spondylolysis, large contained or sequestered lumbar disc 
herniation, evidence of severe disc disruption and insufficient posterior annulus at the level to be 
treated. Patients were followed-up for a minimum of 24 months and data were collected 
prospectively on clinical outcomes (ODI, VAS, SF-36), radiographic evaluations and NHS resource use. 
No information was collected on return to employment. One hundred patients were recruited to the 
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study. Fifteen patients were excluded from analysis because of protocol violations (previous spinal 
fusion (4 patients), aged under 18 (1 patient)), missing patient data at baseline (7 patients), and lost 
to follow-up within 6 months of the IDET procedure (3 patients)). Patient-level data were available 
for 85 IDET patients.  
 
Patient outcomes 
Patient outcomes were measured by changes in VAS pain score, ODI disability rating and health-
state utility. Health-state utilities were derived for each patient from SF-36 responses collected at 
baseline (pre-operatively) and at 6, 12 and 24 months post-operatively, by first converting SF-36 to 
SF-6D14 and then applying the coefficients of the SF-6D mean model.15 Quality adjusted life years 
(QALY) were calculated using the ‘area under the curve’ approach.16 
 
Resource use and costs 
Information on the use of NHS resources was collected for each patient from a review of clinical 
records and included operating theatre time, procedure-related disposables (catheters, needles and 
fixators), hospital inpatient stay and subsequent injections for pain relief and surgical interventions 
related to the original condition (including wound wash-out, debridement, revision surgery for FRA 
patients and fusion or disc replacement surgery for IDET patients).  Resource items were costed at 
2005/06 QMC prices or published national average unit costs. For FRA patients, unit costs are those 
reported in Freeman, et al (2007).9 Resource items specific to IDET patients (such as catheters and 
needles) were costed at representative UK prices in 2005/06 supplied by the manufacturer.  Costs 
and utilities were discounted at 3.5% in line with recommendations of the National Institute for 
Health and Clinical Excellence (NICE, 2008).17  
 
Missing data treatment 
For patients in the FRA group, information was missing on theatre time (2/37 patients) for the 
primary fusion operation and length of stay for 2/7 patients who underwent a revision procedure. 
For IDET patients information was missing on the number of catheters used during the initial 
procedure (7/85 patients), and on implants used (2/18), theatre time (3/18) and length of stay (2/18) 
for patients undergoing subsequent procedures. 
 
Utility scores (Table 1) were available for 95% (36/37) of FRA patients at baseline and at the 24-
month follow-up. Information was missing for 18.9% of patients at 6 months (7/37), and for 13.5% 
(5/37) at 12 months.  These patients either did not attend a particular follow-up appointment or 
failed to complete the SF-36 questionnaire. None withdrew or was lost to follow-up. In the IDET 
group, utility information was available for 96% (82/85) of patients at baseline and for 84.7% (72/85) 
at 6 months.  Missing information was due to the patient failing to attend the 6-month follow-up 
appointment, or failing to complete the SF-36. Between 6 months and 12 months, 7 patients were 
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lost to follow-up and 6 patients withdrew from the study, so that at the 12-month assessment utility 
information was available for 78.8% (67/85). Between 12 months and 24 months, 12 further patients 
were lost to follow-up, 13 withdrew and one patient failed to complete the SF-36. At the 24-month 
assessment, utility information was available for 54% (46/85) of IDET patients. 
 
Patients were withdrawn from the IDET study if the patient and surgeon mutually agreed that the 
procedure had been unsuccessful (as evidenced by persistent pain and disability).  Nineteen patients 
withdrew from the study between 6 and 24 months.  Information was available for 18 of these 
patients on the costs of all subsequent interventions (injections or surgery), and these patients were 
included in the costing analysis. However, patients who withdrew did not complete quality of life 
assessments after that point, and no subsequent utility data were available for these patients. 
 
Three scenarios were constructed to handle missing resource use and utility information. In the base 
case analysis, missing data were imputed on the basis of the mean observed value of costs or 
utilities for each group at the respective time point.  Two extreme cases were also considered in 
which missing data were imputed at the minimum or maximum of observed values. 
 
Data analysis 
The mean difference in costs and QALYs between the two intervention groups, and bias corrected 
and adjusted 95% confidence intervals were estimated using non-parametric bootstrapping.18 
 
Results 
Patient characteristics 
The patient groups were similar in age (mean 39.5 years (FRA) vs 42.3 years (IDET)) and gender (54% 
female in both groups).  The mean pre-treatment VAS score was significantly higher in the FRA 
group, indicating greater pain severity (7.0 (FRA) vs 5.6 (IDET); p=0.0016). The mean pre-treatment 
ODI score was also significantly higher in the FRA group (56.5% (FRA) vs 48.2% (IDET); p=0.0079). 
Mean duration of symptoms was 73 months for the IDET group and 87 months for the FRA group 
(not significant, p=0.472). There were no significant differences between the groups in SF-36 domain 
scores, except physical function (p=0.004) and mental health (p=0.021), both of which were lower in 
the FRA group, indicating lower quality of life. Baseline utility scores were significantly lower in the 
FRA group (0.48 vs 0.52, p=0.03) (Table 1 and Fig 1). 
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Outcomes 
There was no significant difference in re-intervention rates between the two treatments (p=0.1354). 
The re-intervention rate in the FRA treatment group was 32% (12/37). Five patients (14%) required 
injections for pain relief, seven (19%) required some form of additional surgical intervention 
including three (8%) requiring a revision fusion procedure. In the IDET group, the re-intervention 
rate was 47% (40/85). Twenty-six patients (31%) required injections for pain relief and 18 patients 
(21%) required some form of surgical intervention, of which 12 required disc replacement or primary 
fusion (14%).  Four patients required both injections and surgical intervention. 
 
Mean VAS was reduced in both treatment groups between the pre-treatment period and the 24-
month follow-up: from 5.6 pre-treatment to 4.1 (IDET; p=0.001)), and from 7.2 pre-treatment to 5.2 
(FRA; p<0.001)). The difference between the two groups at 24-months was not significant. 
(p=0.0877). Both groups experienced an improvement in low back pain disability (ODI) at 24-months: 
from 48.2% (‘severe disability’) to 37.4% (‘moderate disability’) in the IDET group (p<0.001), and 
from 56.5% (‘severe disability’) to 42.0% (‘severe disability’) in the FRA group (p<0.001). The 
difference between the two treatment groups at 24-months was not significant (p=0.3813).  
 
Both treatment groups experienced a statistically significant increase in utility between the pre-
operative assessment and 24-months post intervention (p<0.001 (IDET); p=0.002 (FRA)) (Table 1 & 
Figure 1). In the IDET group, most of the utility gain was achieved in the first 6 months post-
intervention (0.50 to 0.60) and was sustained to 24-months. In the fusion group the maximum utility 
gain was achieved at 12 months (0.48 to 0.64) and there was some reduction in utility between the 
12 and 24-month assessments (0.64 to 0.58). The absolute increment in utility was the same for 
both treatment groups. 
 
Cost-effectiveness  
NHS costs were lower with IDET irrespective of the method of imputing missing values, primarily due 
to the shorter procedure time and length of stay associated with the IDET procedure. Mean 
(primary) procedure time per patient was 377.4 minutes (FRA) compared with 49.9 minutes (IDET), 
and mean length of stay was 7.0 days (FRA) vs 1.2 days (IDET).   Even including all subsequent 
surgical interventions, procedure time and length of stay remained shorter in the IDET group.   
 
The cost difference between IDET and FRA was not sensitive to the method of imputation.  The 
difference in QALY gains was more sensitive to the method of imputation because of the relatively 
greater amount of missing information on utility, particularly in the IDET group (Table 2). The 
following points summarize the major findings of each imputation method: 
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 Imputing missing values at the mean of observed values, IDET is a dominant treatment 
option. The mean incremental cost of IDET was -£3,713 per patient (95% CI = -£2,684 to -
£4,742) and the mean incremental QALY gain, adjusted for baseline utility scores, was 0.03 
(95% CI = -0.07 to 0.12).  At a threshold of £20,000 per QALY the probability that IDET is cost-
effective is 1, and the net health benefit is 0.21 QALY per patient treated. At £30,000 per 
QALY the probability is 0.99 and net health benefit is 0.15 QALY. 
 Imputing at minimum values, the incremental cost of IDET was -£3,712 (95% CI = -£2,719 to -
£4,707) and the adjusted incremental QALY gain was –0.05 (95% CI = -0.16 to 0.057). The 
incremental cost of fusion was £74,200 per QALY (£3,712/0.05). At a threshold of £20,000 
per QALY the probability that IDET is cost-effective is 1, and the net health benefit is 0.14 
QALY per patient treated. At £30,000 per QALY the probability is 0.99 and net health benefit 
is 0.08 QALY.   
 Imputing at maximum values, IDET is dominant.  The incremental cost of IDET was -£3,657 
(95% CI = -£2510 to -£4,802) and the expected QALY gain was 0.11 (95% CI = 0.01 to 0.22). At 
a threshold of £20,000 per QALY the probability that IDET is cost-effective is 1, and the net 
health benefit is 0.3 QALY per patient treated. At £30,000 per QALY the probability is 1 and 
net health benefit is 0.23 QALY.   
 
Figure 2 shows incremental QALYs and cost per patient resulting from a decision to select IDET 
rather than FRA, using the mean imputation method. The expected cost saving with IDET was £3,713 
per patient (95% CI = £2,684 to £4,742) and the mean QALY gain was 0.03 per patient (95% CI = -0.07 
to 0.12). IDET is a dominant treatment option. 
 
Discussion 
Both of the treatments considered in this analysis were effective in relieving the symptoms 
associated with discogenic low back pain. Both treatments produced statistically significant 
improvements in back and leg pain, low back pain disability and health-state utility compared with 
the pre-intervention assessment. Most of the improvement was sustained for at least 2 years. 
Neither procedure was completely successful in all patients. Overall re-intervention rates were 32% 
for the FRA group and 47% for the IDET group (p=0.1354). However, most patients required only one 
subsequent injection for pain relief and the numbers requiring an additional surgical procedure were 
relatively low: 19% in the FRA treatment group and 21% in the IDET group.  
 
Expected costs to the NHS were £3,261 per patient in the IDET group and £6,974 for patients in the 
FRA group (Table 2). This includes the cost of re-intervention (and/or the cost of other treatments 
for the patients who were withdrawn from IDET for lack of treatment efficacy. Costs were still lower 
with IDET, despite a slightly higher re-intervention rate, because IDET is a less invasive procedure 
which can normally be carried out on an outpatient or day-case basis. Average procedure time and 
post-operative length of stay were both shorter in the IDET group 
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There are several reasons for the delay in reporting these results. When initially presented at 
spinal surgical meetings there was scepticism regarding the utility of IDET. The biggest challenge 
was that any observed treatment effect wound not be maintained or overtaken by progressive 
disc degeneration. To counter this critique, the senior surgical author resolved to delay publication 
to allow an opportunity for ‘failed’ IDETs to return to the regional centre. There was only one 
patient who returned 4 years after an initially successful IDET. A repeat MRI did not show any 
significant accelerated disc failure at the index level. Unfortunately, there is no comparable fusion 
data to allow meaningful comparison with IDET> Despite and perhaps because of the conclusions 
from this study it has not well received in the established spine surgical journals. Despite the time 
lapse, the relative costs of the additional procedures remain the same. The historical inflation rate 
over this period has averaged 3% per annum. 
 
Compared with a ‘no intervention’ baseline, the incremental cost per QALY gained with IDET was 
approximately £15,500. Expected QALYs in the two years post-baseline were 1.02 (no intervention) 
and 1.23 (IDET), an overall gain of 0.21 QALY over the two years with IDET. The expected cost of IDET 
was £3,261 and the incremental cost per QALY gained was therefore £15,500 (£3,261/0.21).  At an 
implicit threshold of £20k-£30k per QALY, there is a high probability that IDET is cost-effective. On 
the same basis, the incremental cost per QALY gained with FRA would be £33,200 (£6,974/0.21).  
The ‘no intervention’ baseline assumes no change in utility from baseline and no costs to the NHS, 
which is conservative. 
 
Comparing IDET and FRA directly, IDET is dominant because expected costs are lower (the mean 
difference per patient was -£3,713) for a similar improvement in quality-adjusted life years (the 
mean difference in favour of IDET was 0.03, but this difference was not statistically significant).  A 
direct comparison between the two treatments is complicated by the fact that the two patient 
groups were drawn from separate trials, rather than from a single randomized study with 
contemporaneous recruitment. IDET was introduced at QMC in January 2001 and was not available 
to patients during the period of recruitment into the FRA study (February 1998 to October 2000). 
However, fusion surgery was a treatment option for patients who did not meet the criteria for IDET.  
The mean ages of patients in the two studies were similar, but the FRA group appeared to have 
more severe symptoms at baseline as evidenced by differences in pre-treatment VAS, ODI and utility 
scores. Inclusion and exclusion criteria were similar for both of the studies, with two exceptions: loss 
of disc height and inclusion of spondylolisthesis. Patients included in the FRA trial had to have loss of 
disc height of 50% or more, whereas patients with more than 50% loss of disc height were excluded 
from receiving IDET. This may indicate that FRA patients had more advanced disc degeneration, 
although there is no necessary correlation between disc degeneration and the extent of disability. 
This does not, in our view, represents significant bias between the two treatment modalities. 
Spondylolisthesis (up to Meyerding grade I) was allowed in the FRA trial while patients with any 
spondylolisthesis were not eligible for IDET.   
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No FRA patients were lost to follow-up or were withdrawn from the study.  In the IDET group, 9 
patients were lost to follow-up. Resource use and utility data were available for these patients up to 
the point at which they were lost to follow-up. A further 19 patients were withdrawn from the study 
because the procedure was not successful. Information was available for 18 of these patients on 
resource use, but not on quality of life. Inputting utility scores for these patients on the basis of the 
mean values observed in the IDET group may overestimate utility gains, although it is important to 
note that most of the utility gain in the IDET group was achieved by the 6-month assessment.  
Further research would be valuable to confirm the utility gains associated with the IDET procedure. 
Overall, IDET costs less than FRA and is more QALY efficient with expected further reduction of 
IDET costs as it does not appear that surgical costs have been reduced over time. 
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Table 1: Utility scores 
 Fusion IDET 
 Observations Mean value Observations Mean value 
Pre-operative 
6-months 
12-months 
24-months 
36 
30 
32 
36 
0.48 
0.58 
0.64 
0.58 
82 
72 
67 
46 
0.52 
0.60 
0.60 
0.62 
 
 
Table 2: Expected costs and QALYs 
Imputation 
method 
Treatment 
group 
Expected cost (per 
patient) 
Expected QALY 
(per patient) 
unadjusted 
ICER 
 
Mean IDET 
Fusion 
£3261 
£6974 
1.23 
1.16 
Dominant 
- 
Min IDET 
Fusion 
£3140 
£6852 
1.08 
1.09 
- 
£74,200*  
Max IDET 
Fusion 
£3550 
£7207 
1.39 
1.23 
Dominant 
- 
 
* calculated on parameter estimates adjusted for baseline utility scores 
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Figure 1: Utility scores at baseline, 6, 12 and 24 months 
 
 
 
Figure 2: Incremental cost and incremental QALY (IDET-FRA), mean imputation method. This figure 
shows that for similar degrees of effectiveness, IDET is less costly than FRA.    
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Figure 3: Pie chart demonstrating percentage of other interventions needed after FRA. 
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Figure 4: Pie chart demonstrating other interventions needed after IDET 
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